European Biopharmaceutical Review |
 |
|
|
|
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world. |
 |
| |
|
|
|
|
| Daniel Levy reviews the trends that have taken place in the biotech industry and considers the driving forces that will have an effect on the next generation of drugs. |
|
|
| How can the pharmaceutical industry continue to push forward research in the current climate of restructuring and reduced budgets? Stewart Lyman at Lyman BioPharma Consulting LLC believes that the solution is to collaborate with academia and ensure that the partnership is managed carefully. |
|
|
| Several models for public-private partnerships have been developed by various organisations to get the most from the knowledge being generated across the industry. Celia Caulcott at the Biotechnology and Biological Sciences Research Council reviews some of the schemes that have been taking place across Europe. |
|
|
| John Avellnet at Cerulean Associates LLC promotes the use of cross-functional stage gates - structured review sessions at which go/no-go decisions need to be made with predefined next steps - to reduce financial losses and risk to clients, and speed time to market. |
|
|
|
| Systemic lupus erythematosus can be extremely difficult to diagnose and the current treatments available can have significant side effects. Jacoba van der Gaag and Clare Davies at Datamonitor look at the specific challenges that this disease poses to drug developers and examine the latest therapeutic developments. |
|
|
| Adel Mahmoud at Princeton University reviews the research taking place in the field of vaccine development and reflects on the potential for future advances in vaccine science and discovery. |
|
|
|
|
| High-throughput screening is the most widely used method of discovering compounds with therapeutic activity; Marc Conti, Corine Matar, Alexandre Ismail and Joshua Franck at BioQuanta argue that complementing it by additional toxicity assessment techniques is the key to reducing late stage failures. |
|
|
| Biochemical and molecular biomarkers have long been crucial to the industry, but now it is the turn for imaging biomarkers to step forward. Josep Prous at Thomson Reuters examines their advantages and potential, and assures us that they are here to stay. |
|
|
| Reducing the blood sample volumes for biological analysis is a real necessity, and one solution gaining interest is dried blood spot sampling. Sally Hannam, John Allinson and Ray Briggs at ICON Development Solutions review the use of this technique and compare it with others. |
|
|
| Therapeutic antibodies have become one of the fastest growing drug classes in pharmaceuticals over the last decade, as well as an integral part of the treatment of cancer patients. Mark Reisenauer at Micromet Inc examines the impact that the next generation of antibody approaches will have on oncology. |
|
|
|
There is increasing interest in the glycosylation of biopharmaceuticals in drug development, Hans Baumeister and Steffen Goletz at Glycotope look at various methods of optimising the process. |
|
|
|
|
Opioids are crucial in combating acute pain, but there are many risks associated with their use, including abuse and overdosing. Edgar H Adams and Vanesa Castillo at Covance argue that implementing opioid class risk evaluation and mitigation strategies will mean that abuse and diversion can be more easily monitored and addressed. |
|
|
| The process of developing new drugs is continually facing new challenges, but it is possible to reap advantages in clinical trials by designing them to make use of modelling and adaptation, explains Tom Parke at Tessella plc. |
|
|
| Thomas Ermlich at Medidata Solutions lays down the idea that the three bedrocks of a successful eClinical strategy are process optimisation, technology implementation and industry knowledge, and that leaving out any of these will produce gaps that can seriously jeapardise results and lead to regulatory penalties. |
|
|
|
| Ian Lafferty and Emma Mickley at R5 Pharmaceuticals discuss how the requirement for TSE-free certification of biotechnology-derived products can be a sticking point for small biotech companies in the earlier stages of formulation and final proudct process development. |
|
|
| Companies using microbial or eukaryotic cells can face dire consequences if bioprocesses become contaminated. Marcin Los at Phage Consultants investigates the various causes and types of contamination, and suggests steps that businesses can take to protect their facilities. |
|
|
|
| The region of Andalusia in the south of Spain is aspiring to become a leader in research into advanced therapies and their translation into clinical research settings. Natividad Cuende and José L Zugaza at the Andalusian Initiative for Advanced Therapies look at the latest developments taking place in the biomedical arena. |
|
|
| Paulo C De Miranda at the International Association of Science Parks (IASP) discusses how science, technology and research parks bring together a wealth of knowledge, information and ideas, with a particular focus on Central and South America. |
|
|
| China's pharmaceutical and biotech market is booming, and the industry cannot afford to miss the opportunities on offer. Darren Ji at PharmaLegacy Laboratories takes a close look at the incentives and challenges facing innovation and productivity in drug development. |
|
|
|
|
|
